Basic/Clinical Science Session
Novel Therapeutic Approaches and Pathways for Phosphate and Fibroblast Growth Factor 23 Regulation
November 06, 2025 | 02:00 PM - 04:00 PM
Location: Room 370A, Convention Center
Session Description
Disordered mineral metabolism, including alterations in phosphate and fibroblast growth factor 23 (FGF23), are strongly associated with adverse outcomes in kidney diseases. Current treatment options are limited, in part because of incomplete understanding of the underlying physiology of phosphate and FGF23 regulation in health and disease. Emerging insights along these lines have the potential to identify new therapeutic opportunities relevant to AKI, CKD, and ESKD.
Learning Objective(s)
- Describe how vitamin D regulation in the intestine can affect systemic mineral metabolism
- Explain how systemic vs. bone effects of phosphate can be separated
- Distinguish the role of phosphate in AKI and its complications
- Describe the potential adverse role for calciprotein particles in CKD and ESKD
Learning Pathway(s)
- Bones‚ Stones‚ and Mineral Metabolism
Moderators
Presentations
- Differential Impacts of Intestinal vs. Renal Vitamin D Metabolism
02:00 PM - 02:30 PM
- Glycerol-3-Phosphate Metabolism in CKD-MBD
02:30 PM - 03:00 PM
- Phosphate Restriction and AKI
03:00 PM - 03:30 PM
- Calciprotein Particles in CKD and Its Complications
03:30 PM - 04:00 PM